A doctor travelling from Greece to Cyprus to carry out cosmetic injectable treatments had pharmaceutical products seized upon arrival at Larnaca Airport, following a customs inspection.
The doctor had reportedly been promoted by a private hospital in Cyprus in recent weeks through online advertisements announcing his visit to perform injectable cosmetic procedures, including botulinum toxin treatments. The advertisements are said to have prompted the Pharmaceutical Services to alert both the Police and the Customs Department.
Upon arrival, customs officers searched his luggage and discovered injectable pharmaceutical products as well as anaesthetic solutions whose origin has not yet been established.
Notably, the packaging did not contain usage instructions or labelling in either Greek or English, raising questions about the legality of their importation and intended use.
Authorities are investigating the origin of the products, the conditions under which they were transported and whether they were intended for the scheduled cosmetic procedures.
Customs Department clarifies details
In an official statement, the Customs Department said the inspection took place on 24 October 2026 following an intelligence-led risk assessment and with the assistance of officers from the Directorate for Combating Organised Crime (DAOE) and the Drug Law Enforcement Unit (YKAN).
Customs officers found:
- Five vials containing a liquid used in cosmetic procedures.
- One vial containing an anaesthetic liquid.
The six vials were initially detained while guidance was sought from the competent Pharmaceutical Services.
On 27 October, customs authorities were informed that the products did not hold a licence for circulation in the Republic of Cyprus.
The products were subsequently confiscated for violating Article 9 of the Law on Medicinal Products for Human Use.
Investigation continues
The case remains under investigation by Larnaca Customs.
The official announcement refers to the seizure of six vials but does not confirm that the passenger was arrested.
The incident has renewed warnings from the Pharmaceutical Services about the risks associated with the use of unlicensed injectable products, particularly where their origin, quality and storage conditions cannot be verified.
